Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual CongressGlobeNewsWire • 05/12/21
With 1 Cure Behind It, This Breakthrough Biotech Takes Aim at a Bigger MarketThe Motley Fool • 05/07/21
CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual MeetingGlobeNewsWire • 04/28/21
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial ResultsGlobeNewsWire • 04/27/21
Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving TodayBenzinga • 04/26/21
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta ThalassemiaGlobeNewsWire • 04/26/21
Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta ThalassemiaGlobeNewsWire • 04/20/21
CRISPR Therapeutics AG (CRSP) Presents at 20th Annual Needham Virtual Healthcare Conference (Transcript)Seeking Alpha • 04/12/21
CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell FunctionGlobeNewsWire • 04/10/21